Royalty Pharma PLCNASDAQ:RPRX
- LAST PRICE27.1700
- TODAY'S CHANGE (%)-0.2400 (-0.8756%)
- Bid / Lots26.9900/ 1
- Ask / Lots27.4300/ 1
- Open / Previous Close27.2000 / 27.4100
- Day Range
- 52 Week Range
- Volume1,961,691
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Aug 14, 2024
DJ Royalty Pharma Is Maintained at Buy by Goldman Sachs, from 7:21AM ET on Wednesday Aug 14, 2024 by Dow Jones
7:21AM ET on Wednesday Aug 14, 2024 by Dow Jones
Aug 8, 2024
Royalty Pharma Reports Second Quarter 2024 Results, from 7:00AM ET on Thursday Aug 08, 2024 by Dow Jones
7:00AM ET on Thursday Aug 08, 2024 by Dow Jones*DJ Royalty Pharma 2Q Net $102M >RPRX, from 7:00AM ET on Thursday Aug 08, 2024 by Dow Jones
7:00AM ET on Thursday Aug 08, 2024 by Dow Jones
Jul 24, 2024
Press Release: Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital, from 8:30AM ET on Wednesday Jul 24, 2024 by Dow Jones
8:30AM ET on Wednesday Jul 24, 2024 by Dow JonesRoyalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital, from 8:30AM ET on Wednesday Jul 24, 2024 by Dow Jones
8:30AM ET on Wednesday Jul 24, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Royalty Pharma PLC | 16.2B | 18.1x | +1.83% |
Amneal Pharmaceuticals Inc | 2.5B | -14.2x | --- |
Endo Inc | 2.1B | -0.8x | --- |
Catalent Inc | 10.8B | -9.2x | --- |
Jazz Pharmaceuticals PLC | 6.9B | 19.1x | -3.53% |
Mallinckrodt PLC | 1.6M | --- | --- |
Company Information
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Contact Information
- Headquarters
- 110 East 59th StreetNEW YORK, NY, United States 10022
- Phone
- 212-883-0200
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Pablo Legorreta
- Vice Chairman, Executive Vice President
- Christopher Hite
- Chief Financial Officer, Executive Vice President
- Terrance Coyne
- Executive Vice President - Investments and Chief Legal Officer
- George Lloyd
- Executive Vice President - Head of Human Capital
- Molly Sawaya
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.2B |
|---|---|
Revenue (TTM) | $2.2B |
Shares Outstanding | 597.4M |
Dividend Yield | 3.09% |
Annual Dividend Rate | 0.8400 USD |
Ex-Dividend Date | 08-16-24 |
Pay Date | 09-13-24 |
Beta | 0.46 |
EPS | $1.50 |
Book Value | $14.61 |
P/E Ratio | 18.1x |
Price/Sales (TTM) | 7.3 |
Price/Cash Flow (TTM) | 19.3x |
Operating Margin | 42.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
